May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Somatostatin in Dominant Cystoid Macula Dystrophy
Author Affiliations & Notes
  • B.F. Hogewind
    Ophthalmology, UMCN St Radboud, Nijmegen, The Netherlands
  • K.F. W. Vandoninck
    Ophthalmology, UMCN St Radboud, Nijmegen, The Netherlands
  • J.E. Keunen
    Ophthalmology, UMCN St Radboud, Nijmegen, The Netherlands
  • C.B. Hoyng
    Ophthalmology, UMCN St Radboud, Nijmegen, The Netherlands
  • Footnotes
    Commercial Relationships  B.F. Hogewind, None; K.F.W. Vandoninck, None; J.E. Keunen, None; C.B. Hoyng, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 547. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B.F. Hogewind, K.F. W. Vandoninck, J.E. Keunen, C.B. Hoyng; Somatostatin in Dominant Cystoid Macula Dystrophy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):547.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Dominant Cystoid Macula Dystrophy (DCMD) is an autosomal dominant retinal dystrophy defined by leaking capillaries; especially perimacularly. Since somatostatine analogues like octreotide have a suggested positive effect in macular edema, we hypothesized that somatostatin could also have an positive effect on the early stages of DCMD. Methods: In this prospective study fluoresceine angiography (FAG) and vision acuity were assessed of 10 proven DCMD patients. OCT was performed in 2 patients and ERG/EOG in 3 patients. Each patient received 10 mg somatostatin IM once every six weeks. After 4 and 8 months we repeated the FAG, the vision examination and we measured eventual subjective decline or improvement. Results: At 8 months after treatment, all patients showed clear remission of the the edema on the FAG and on the OCT. 1 Patient showed significant improvement of vision, the other 9 did not show any significant changes. 8 Patients claimed subjective improvement, 2 patients did not experience any visual changes. Conclusions: The results show clear remission of the edema in DCMD, though there is no significant vision improvement. This study shows that somatostatin has a positive effect in the pathogenesis of DCMD, but more research needs to be done to analyse if vision decrease can be stabilized in the long run of the disease.

Keywords: macula/fovea • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.